Balchem Co. (NASDAQ:BCPC - Get Free Report) was down 84.6% on Wednesday . The stock traded as low as $163.39 and last traded at $25.11. Approximately 4,270 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 119,154 shares. The stock had previously closed at $163.39.
Wall Street Analyst Weigh In
A number of research firms have commented on BCPC. StockNews.com upgraded Balchem from a "hold" rating to a "buy" rating in a research report on Monday, October 28th. HC Wainwright boosted their price objective on shares of Balchem from $185.00 to $190.00 and gave the stock a "buy" rating in a research report on Monday, November 4th.
View Our Latest Report on Balchem
Balchem Trading Down 2.5 %
The business has a 50 day moving average of $165.18 and a 200-day moving average of $170.24. The stock has a market cap of $5.21 billion, a PE ratio of 43.09, a price-to-earnings-growth ratio of 4.42 and a beta of 0.69. The company has a current ratio of 2.98, a quick ratio of 1.90 and a debt-to-equity ratio of 0.21.
Balchem Increases Dividend
The business also recently disclosed an annual dividend, which was paid on Friday, January 17th. Investors of record on Thursday, December 26th were paid a dividend of $0.87 per share. The ex-dividend date was Thursday, December 26th. This represents a dividend yield of 0.4%. This is a positive change from Balchem's previous annual dividend of $0.79. Balchem's dividend payout ratio (DPR) is presently 23.39%.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in BCPC. HighTower Advisors LLC boosted its stake in shares of Balchem by 10.0% during the 4th quarter. HighTower Advisors LLC now owns 2,452 shares of the basic materials company's stock worth $400,000 after purchasing an additional 223 shares during the last quarter. Inspire Advisors LLC grew its stake in Balchem by 3.2% in the 4th quarter. Inspire Advisors LLC now owns 5,123 shares of the basic materials company's stock worth $835,000 after acquiring an additional 161 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Balchem by 21.7% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,471 shares of the basic materials company's stock valued at $1,381,000 after acquiring an additional 1,510 shares during the last quarter. AlphaQuest LLC raised its holdings in Balchem by 331.6% in the 4th quarter. AlphaQuest LLC now owns 7,955 shares of the basic materials company's stock valued at $1,297,000 after acquiring an additional 6,112 shares during the last quarter. Finally, Amundi lifted its stake in shares of Balchem by 151.3% during the 4th quarter. Amundi now owns 19,096 shares of the basic materials company's stock worth $3,000,000 after purchasing an additional 11,496 shares during the period. Institutional investors and hedge funds own 87.91% of the company's stock.
Balchem Company Profile
(
Get Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Featured Stories
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.